HC Wainwright & Co. Reiterates Buy on Uranium Energy, Maintains $8 Price Target

Publications And Positive Data From Multiple Trials: Six Months In Review For Tiziana Life Sciences (NASDAQ: TLSA)

Tiziana Life Sciences is a biotechnology company establishing itself in a cutting-edge position in the marke t with its breakthrough immunomodulation therapies. The past six months have been an exciting time for the company, whose main drug candidate is the intranasally-delivered foramulab. Foramulab is the first fully human anti-CD3 monoclonal antibody (mAB), and it is able to effectively suppress neuroinflammation in the central nervous system. The global market for mAB treatments was worth $210 billion in 2022 , and it is expected to grow at a compound annual growth rate (CAGR) of 11% between 2023 and 2030. In 2023 a major development in the mAB market came when Sanofi agreed to acquire Provention Bio for $2.9 billion for the anti-CD3 mAB, teplimuzab. This acquisition revealed the biomedical market’s serious interest in anti-CD3 […]

Click here to view original web page at www.benzinga.com

About the author: StockMan

Please remember:

The information provided here is for general knowledge and educational purposes only.
It is not intended to be a substitute for professional financial advice.
Every individual's financial situation is unique, and what works for one person may not work for another.
Before making any investment or financial decisions, you should always consult with a qualified financial advisor who understands your specific circumstances and goals.

Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, should never be acted upon. Please be aware that any information posted on this site should not be considered to be financial advice and i am not a financial advisor.